# Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

> **NCT05097209** · PHASE2 · UNKNOWN · sponsor: **Wei Jiang** · enrollment: 200 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Gemcitabine
- **DRUG:** Induction Cisplatin
- **RADIATION:** intensity-modulated radiotherapy
- **DRUG:** Concurrent cisplatin

## Key facts

- **NCT ID:** NCT05097209
- **Lead sponsor:** Wei Jiang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-06
- **Primary completion:** 2025-04-06
- **Final completion:** 2026-04-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097209, "Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05097209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*